These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8737142)
21. Evaluation of new therapy for eradication of H. pylori infection in nude mouse model. Karita M; Li Q; Okita K Am J Gastroenterol; 1993 Sep; 88(9):1366-72. PubMed ID: 8362832 [TBL] [Abstract][Full Text] [Related]
22. Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. Irie Y; Tateda K; Matsumoto T; Miyazaki S; Yamaguchi K J Antimicrob Chemother; 1997 Aug; 40(2):235-40. PubMed ID: 9301989 [TBL] [Abstract][Full Text] [Related]
23. Gastroprotective effects of Hwanglyeonhaedok-tang against Helicobacter pylori-induced gastric cell injury. Park HS; Wijerathne CUB; Jeong HY; Seo CS; Ha H; Kwun HJ J Ethnopharmacol; 2018 Apr; 216():239-250. PubMed ID: 29410309 [TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan. Cheng A; Sheng WH; Liou JM; Wang HP; Wu MS; Lin JT; Chang SC J Microbiol Immunol Infect; 2015 Feb; 48(1):72-9. PubMed ID: 23036269 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. Spósito L; Oda FB; Vieira JH; Carvalho FA; Dos Santos Ramos MA; de Castro RC; Crevelin EJ; Crotti AEM; Santos AG; da Silva PB; Chorilli M; Bauab TM J Ethnopharmacol; 2019 Apr; 233():1-12. PubMed ID: 30594606 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity of Aloe vera inner gel against Helicobacter pylori strains. Cellini L; Di Bartolomeo S; Di Campli E; Genovese S; Locatelli M; Di Giulio M Lett Appl Microbiol; 2014 Jul; 59(1):43-8. PubMed ID: 24597562 [TBL] [Abstract][Full Text] [Related]
27. Inhibitory and bactericidal activity of rokitamycin against Helicobacter pylori and morphological alterations. Brenciaglia MI; Fornara AM; Scaltrito MM; Braga PC J Chemother; 1996 Dec; 8(6):425-31. PubMed ID: 8981182 [TBL] [Abstract][Full Text] [Related]
28. Studies on anti-Helicobacter pylori agents. Part 1: Benzyloxyisoquinoline derivatives. Yoshida Y; Barrett D; Azami H; Morinaga C; Matsumoto S; Matsumoto Y; Takasugi H Bioorg Med Chem; 1999 Nov; 7(11):2647-66. PubMed ID: 10632076 [TBL] [Abstract][Full Text] [Related]
29. In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole. Blacky A; Makristathis A; Apfalter P; Willinger B; Rotter ML; Hirschl AM Eur J Clin Microbiol Infect Dis; 2005 Apr; 24(4):276-9. PubMed ID: 15902535 [TBL] [Abstract][Full Text] [Related]
30. In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates. Wang B; Zhao Q; Yin W; Yuan Y; Wang X; Wang YH; Wang H; Ye W; Chen S; Guo HL; Xie Y Swiss Med Wkly; 2018; 148():w14630. PubMed ID: 30044468 [TBL] [Abstract][Full Text] [Related]
31. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. Dai G; Cheng N; Dong L; Muramatsu M; Xiao S; Wang MW; Zhu DX Antimicrob Agents Chemother; 2005 Aug; 49(8):3468-73. PubMed ID: 16048962 [TBL] [Abstract][Full Text] [Related]
32. Microbial ecology and treatment of Helicobacter pylori infections: review. Adamsson I; Edlund C; Nord CE J Chemother; 2000 Feb; 12(1):5-16. PubMed ID: 10768510 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Glupczynski Y; Broutet N; Cantagrel A; Andersen LP; Alarcon T; López-Brea M; Mégraud F Eur J Clin Microbiol Infect Dis; 2002 Jul; 21(7):549-52. PubMed ID: 12172749 [TBL] [Abstract][Full Text] [Related]
34. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. Hassan ST; Berchová K; Majerová M; Pokorná M; Švajdlenka E Pharm Biol; 2016 Sep; 54(9):1736-40. PubMed ID: 26731378 [TBL] [Abstract][Full Text] [Related]
35. The prevalence of primary and secondary Helicobacter pylori resistance to clarithromycin and probable contributing cofactors: data from southeastern Anatolia. Tüzün Y; Bayan K; Yilmaz S; Dursun M; Ozekinci T Hepatogastroenterology; 2008; 55(81):289-93. PubMed ID: 18507127 [TBL] [Abstract][Full Text] [Related]
36. [Antimicrobial susceptibility of Helicobacter pylori with chronic gastritis]. Figueroa M; Cortés A; Pazos Á; Bravo LE Biomedica; 2012; 32(1):32-42. PubMed ID: 23235785 [TBL] [Abstract][Full Text] [Related]
37. Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Markham A; McTavish D Drugs; 1996 Jan; 51(1):161-78. PubMed ID: 8741237 [TBL] [Abstract][Full Text] [Related]
38. Combination therapy with clarithromycin and sofalcone for eradication of Helicobacter pylori. Kodama R; Fujioka T; Fujiyama K; Kawasaki H; Kubota T; Nasu M Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S125-8. PubMed ID: 7735929 [TBL] [Abstract][Full Text] [Related]
39. Promising in vitro and in vivo inhibition of multidrug-resistant Helicobacter pylori by linezolid and novel oxazolidinone analogues. Shi J; Jiang Y; Zhao Y J Glob Antimicrob Resist; 2016 Dec; 7():106-109. PubMed ID: 27718441 [TBL] [Abstract][Full Text] [Related]
40. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. Isomoto H; Furusu H; Ohnita K; Wen CY; Inoue K; Kohno S World J Gastroenterol; 2005 Mar; 11(11):1629-33. PubMed ID: 15786539 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]